ACC 2026 — Dr Deepak Bhatt (Mount Sinai Fuster Heart Hospital, US) delivers his expert verdict on three late-breaking clinical trials from ACC 2026 that are poised to influence cardiovascular care and future clinical guidelines.

Dr Bhatt highlights data updates from the SURPASS-CVOT trial, exploring expanded cardiometabolic findings with tirzepatide versus dulaglutide, discusses the HI-PEITHO trial confirming the benefit of ultrasound-facilitated thrombolysis in intermediate-risk pulmonary embolism, and reviews results from the SURVIV trial demonstrating the safety and efficacy of a transcatheter valve-in-valve approach in patients with a failing bioprosthetic mitral valve.

Together, these studies underscore evolving evidence at the intersection of cardiometabolic disease, interventional management of venous thromboembolism, and structural heart interventions, each with the potential to reshape patient care algorithms in daily practice.

Key Trials Covered Include:
SURPASS-CVOT — Tirzepatide vs Dulaglutide in Cardiovascular Outcomes
HI-PEITHO — Ultrasound-Facilitated Thrombolysis in Intermediate-Risk PE
SURVIV — Transcatheter Valve-in-Valve vs Redo Surgery for Failing Mitral Bioprosthesis

For more expert insights and late-breaking science from ACC 2026, visit the Late-breaking Science Video Collection.

Editor: Jordan Rance, Mirjam Boros
Videographer: David Ben-Harosh, Daniel Brent

Support: This is an independent video produced by Radcliffe Cardiology.